First report of safety and efficacy of daratumumab in 2 cases of advanced immunoglobulin light chain amyloidosis

Blood. 2016 Oct 13;128(15):1987-1989. doi: 10.1182/blood-2016-06-722496. Epub 2016 Aug 19.

Authors

Taimur Sher¹, Brooke Fenton¹, Adnan Akhtar², Morie A Gertz³

Affiliations

¹ Mayo Clinic, Jacksonville, FL.
² Florida Hospital, Orlando, FL; and.
³ Mayo Clinic, Jacksonville, FL; Mayo Clinic, Rochester, MN.

PMID: 27543437
DOI: 10.1182/blood-2016-06-722496

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antibodies, Monoclonal / adverse effects
Antibodies, Monoclonal / therapeutic use*
Disease Progression
Humans
Immunoglobulin Light Chains / blood
Immunoglobulin Light-chain Amyloidosis / blood
Immunoglobulin Light-chain Amyloidosis / drug therapy*
Immunoglobulin Light-chain Amyloidosis / pathology
Male
Middle Aged
Treatment Outcome

Substances

Antibodies, Monoclonal
Immunoglobulin Light Chains
daratumumab